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1. INTRODUCTION {#irv12523-sec-0006}
===============

Seasonal and pandemic influenza virus enters and replicates in cells of the upper respiratory tract where the virus recognizes sialic acid molecules linked to the Gal of glycoprotein on the surface of host epithelial cells.[1](#irv12523-bib-0001){ref-type="ref"} However, viral RNA of these viruses has been detected in stools of patients with confirmed influenza infection[2](#irv12523-bib-0002){ref-type="ref"}, [3](#irv12523-bib-0003){ref-type="ref"}, [4](#irv12523-bib-0004){ref-type="ref"}, [5](#irv12523-bib-0005){ref-type="ref"}, [6](#irv12523-bib-0006){ref-type="ref"}, [7](#irv12523-bib-0007){ref-type="ref"} with an overall reported prevalence of 20.6%.[8](#irv12523-bib-0008){ref-type="ref"} Although the main route of human influenza virus infection is respiratory, gastrointestinal (GI) symptoms such as diarrhea, nausea, vomiting, and abdominal pain are not uncommon manifestations.[9](#irv12523-bib-0009){ref-type="ref"}, [10](#irv12523-bib-0010){ref-type="ref"}, [11](#irv12523-bib-0011){ref-type="ref"}, [12](#irv12523-bib-0012){ref-type="ref"}, [13](#irv12523-bib-0013){ref-type="ref"}, [14](#irv12523-bib-0014){ref-type="ref"}, [15](#irv12523-bib-0015){ref-type="ref"} Currently, only avian influenza virus A(H5N1) is known to replicate in human intestinal tissues[16](#irv12523-bib-0016){ref-type="ref"} and to cause severe GI symptoms.[17](#irv12523-bib-0017){ref-type="ref"} While seasonal and pandemic influenza virus is likely to spread to the GI tract of patients after a primary respiratory infection, the route of dissemination remains unknown. Current knowledge explains the detection of human influenza viruses in feces because of (i) swallowing of influenza viruses from the upper respiratory tract; (ii) remnants of infected submucosal intestinal antigen‐presenting immune cells; and (iii) virus replication in intestinal cells.[8](#irv12523-bib-0008){ref-type="ref"} The significance of the detection of influenza viral RNA in stools, their dissemination on GI tract, their correlation with GI symptoms, and their viability in stool remain unclear and are still debated.[7](#irv12523-bib-0007){ref-type="ref"}, [18](#irv12523-bib-0018){ref-type="ref"}

A recent study reported that while swallowed influenza seasonal viruses are vulnerable to digestive juices, artificial highly viscous mucus (imitating sputum, nasal discharge, and other mucous membrane secretions) seems to protect viral RNA and virions, allowing their detection in feces.[19](#irv12523-bib-0019){ref-type="ref"}

It seems important to identify whether other factors would favor influenza detection in stools with the aim of limit interpretation biases in the future.

Thus, in this prospective study, we investigated for the first time microbiological, demographical, and clinical factors which could influence the presence of influenza viral RNA in stools of patients with laboratory‐confirmed influenza infection. Results from this study will help and inform future studies that investigate the role of human influenza virus in stools.

2. MATERIAL AND METHODS {#irv12523-sec-0007}
=======================

2.1. Ethic {#irv12523-sec-0008}
----------

This study was approved by the ethics committee (CPP V, ref number 14.078). The protocol was conducted in accordance with the Helsinki Declaration. All samples were coded and tested anonymously. None of the authors collected samples. Samples were collected and sent to the test laboratory by general practitioners (GPs) involved in the research project. Patient information was stored according to national regulations, and access to such data was restricted (permission CNIL 471393). The patient\'s identities were not disclosed at any stage. Written informed consent was obtained from patients by the GP\'s. For children under the age of 18, parents or legal guardians gave permission for their participation in this project. Consent from the child was also obtained, depending on her/his age and maturity.

2.2. Design and study population {#irv12523-sec-0009}
--------------------------------

This is a prospective, observational, cross‐sectional study, conducted in patients consulting a GP of the French *Sentinelles* Network[20](#irv12523-bib-0020){ref-type="ref"} for an acute respiratory infection (ARI) during two winter seasons, from November 2014 to April 2015 and from November 2015 to April 2016. The case definition of ARI was "any person with a sudden onset of symptoms and at least one of the following four systemic symptoms: fever or feverishness, malaise, headache, myalgia, AND at least one of the following three respiratory symptoms: cough, sore throat, or shortness of breath." All patients were recruited within 48 hours of the onset of symptoms.

2.3. Data collected {#irv12523-sec-0010}
-------------------

Two types of samples were obtained for each enrolled patient: a nasopharyngeal swab and a stool sample. The nasopharyngeal specimen was collected by the GP and was sent with the case report form (CRF) to the test laboratory by post in a triple packaging as required by the United Nations class 6.2 specifications. The CRF included variables such as age, sex, professional status, seasonal influenza vaccination, ARI signs and symptoms, GI symptoms, presence of chronic disease, risk factors for severe influenza, travel 15 days before consultation, drug consumption 7 days before consultation (antiviral and/or antibiotic and/or anti‐inflammatory and/or antipyretics and/or other), consumption of particular foods (tap water, oysters, mussels and/or shellfish, cooked or raw), depression, drug prescription, and required hospitalizations. Included patients were asked to collect stool specimens and send them to the laboratory within 48 hours after GP consultation by post in triple packaging as required by the United Nations class 6.2 specifications.

3. LABORATORY INVESTIGATIONS {#irv12523-sec-0011}
============================

3.1. Nucleic acid extraction {#irv12523-sec-0012}
----------------------------

For nasopharyngeal specimens, nucleic acids were extracted from 200 μL of UTM‐stored sample and eluted in 60 μL of elution buffer using QiAamp MinElute virus spin kits (Qiagen, France) according to the manufacturer\'s instructions. Stool specimens were centrifuged at 20 817× *g* for 20 minutes; then, nucleic acids were extracted from 200 μL of the UTM‐stored sample and eluted in 40 μL of elution buffer using QiAamp MinElute virus spin kits (Qiagen) according to the manufacturer\'s instructions. An internal control (T4 and MS2 phages) was added to each extraction tube to assess the quality of the extraction at the end of the amplification.[21](#irv12523-bib-0021){ref-type="ref"}

3.2. Quantitative reverse transcriptase polymerase chain reaction (RT‐qPCR) tests {#irv12523-sec-0013}
---------------------------------------------------------------------------------

A RT‐qPCR test was considered positive if it passed internal positive controls and had an exponential curve. Samples were excluded if the internal control value had a cycle threshold (Ct) value \>35.

### 3.2.1. Detection of influenza viruses {#irv12523-sec-0014}

All extracted samples (nasopharyngeal and stool) were screened for influenza A and B viruses by RT‐qPCR; influenza A virus‐positive specimens were subtyped, and influenza B virus‐positive samples were analyzed for Victoria and Yamagata lineage according to the method developed by the French National Influenza Centre.[22](#irv12523-bib-0022){ref-type="ref"}

### 3.2.2. Detection of other respiratory pathogens {#irv12523-sec-0015}

For all extracted samples (nasopharyngeal and stool), the presence of 10 non‐influenza respiratory pathogen groups was analyzed by RT‐qPCR using a Fast Track Diagnostic (FTD) Respiratory pathogens 21 kit (Fast Track Diagnostic, Luxemburg) for the presence of human *Rhinovirus* (HRV), human *Coronaviruses* NL63 (HCoV‐NL63), 229E (HCoV‐229E), OC43 (HCoV‐OC43), and HKU1 (HCoV‐HKU1), human *Parainfluenza* viruses 2, 3, and 4 (HPIV‐2, 3, and 4) and internal control, human *Parainfluenza* virus 1, *Mycoplasma pneumoniae* (*M. pneu*), human *Bocavirus* (HBoV), human *Metapneumovirus* (HMPV A/B)\] and *respiratory syncytial virus* (RSVA/B), human *Adenovirus* (HAdV), *Enterovirus* (EV), and human *Parechovirus* (HPeV).

### 3.2.3. Detection of enteric pathogens {#irv12523-sec-0016}

Extracted stool samples were screened by qPCR and RT‐qPCR using the FTD viral gastroenteritis and bacterial gastroenteritis kits (Fast Track Diagnostic, Luxemburg) to detect six viruses and six bacteria: human *Norovirus* (hNoVG1 and hNoVG2), human *Adenovirus* (HAdV), human *Astrovirus* (HAstV), *Rotavirus* (RV) and *Sapovirus* (SaV), *Campylobacter coli/jejuni/lari, Escherichia coli verotoxin positive, Salmonella* spp, *Shigella* spp* + enteroinvasive Escherichia coli, Yersinia enterocolitica, Clostridium difficile*.

3.3. Influenza virus isolation {#irv12523-sec-0017}
------------------------------

Nasopharyngeal and stool specimens that were positive for influenza virus were inoculated onto Madin‐Darby canine kidney (MDCK) tissue cells with an aliquot of clinical specimens and incubated for 7 days using a method reported previously.[5](#irv12523-bib-0005){ref-type="ref"}

3.4. Statistical analysis {#irv12523-sec-0018}
-------------------------

Quantitative variables described using median \[Min‐Max\] and mean with standard deviations (SD) were compared by the Wilcoxon test. Qualitative variables were described using proportions and compared using a chi‐square or Fisher\'s exact test if the chi‐square test was not applicable. Factors associated with the detection of influenza seasonal viruses in stools were evaluated by bivariate and multivariate logistic regression analyses. Variables for the model were chosen through automatic backwards selection using Akaike information criterion (AIC). A *P*‐value \<.05 was considered statistically significant in all tests. Results were presented as odds ratio with 95% confidence intervals (OR \[95% CI\]). All analyses were performed using the R 3.4.1 program (<http://www.r-project.org>).

4. RESULTS {#irv12523-sec-0019}
==========

Overall, 331 ARI patients (with nasopharyngeal and stool samples) were enrolled by GPs. Influenza virus was identified in 34.4% (114/331) of nasopharyngeal samples. The median age of patients was 34 years \[1‐88\] and 46.5% (53/114) were male. At least one GI symptom was declared in 57.9% (66/114) of influenza cases: Diarrhea was reported by 13.2% (15/114), vomiting by 8.8% (10/114), nausea by 28.9% (33/114), and abdominal pain by 40.4% (46/114). Influenza viral RNA was detected in 21% (24 of 114) of stool specimens. Table [1](#irv12523-tbl-0001){ref-type="table"} shows and compares the demographical and clinical data, and the management of influenza patients with positive (N = 24) and negative (N = 90) fecal viral RNA detection.

###### 

Descriptive statistics, odds ratios, and 95% confidence intervals bivariate and multivariate models of the risks of fecal viral RNA‐positive detection

  Patient Characteristics                                   Fecal viral RNA positiveN = 24 (%)   Fecal viral RNA negativeN = 90 (%)   OR[b](#irv12523-note-0001){ref-type="fn"} \[95% IC\](*P*‐value)   aOR[c](#irv12523-note-0002){ref-type="fn"} \[95% CI\](*P*‐value)
  --------------------------------------------------------- ------------------------------------ ------------------------------------ ----------------------------------------------------------------- ------------------------------------------------------------------
  Clinical characteristics                                                                                                                                                                              
  Male sex, no (%)                                          14 (58.3)                            39 (43.3)                            2.5 \[0.8‐8.7\] (0.1)                                             2.5 \[1.0‐6.7\] (0.05)
  Mean age, y (SD)[a](#irv12523-note-0101){ref-type="fn"}   37.4 ± 21.4                          33.3 ± 22.2                                                                                            
  0‐4 y                                                     2 (8.3)                              5 (5.6)                              0.33 \[0.01‐7.3\] (0.6)                                           
  5‐14 y                                                    6 (25)                               20 (22.2)                            0.45 \[0.04‐5.5\] (0.6)                                           
  15‐44 y                                                   4 (16.6)                             37 (41.1)                            0.17 \[0.02‐1.8\] (0.2)                                           
  45‐64 y                                                   9 (37.5)                             21 (23.3)                            1.8 \[0.3‐17.2\] (0.6)                                            4.8 \[1.7‐14.5\] (0.01)
  \>65 y                                                    3 (12.5)                             7 (7.7)                              0.6 \[0.04‐8.4\] (0.7)                                            
  Digestive disorders \<7 days                              4 (16.67)                            9 (10)                               2.6 \[0.48‐12.7\] (0.3)                                           
  Vaccination against seasonal influenza                    2 (8.3)                              7 (7.8)                              0.4 \[0.04‐46\] (0.6)                                             
  Influenza risk factors                                    7 (29)                               27 (30)                              0.6 \[0.1‐2.7\] (0.6)                                             
  Hospitalization                                           3 (12.5)                             6 (6.7)                              7.0 \[1.1‐45\] (0.07)                                             7.8 \[1.7‐33.7\] (0.02)
  High fever (\>39°C)                                       17 (70.8)                            54 (60)                              2.8 \[0.8‐11.7\] (0.19)                                           2.6 \[1.7‐33.7\] (0.1)
  Dyspnea                                                   7 (29.2)                             18 (20)                              2.2 \[0.6‐8.8\] (0.33)                                            4.4 \[1.1‐20\] (0.05)
  Gastrointestinal symptoms                                 13 (54.17)                           53 (58.89)                           0.8 \[0.2‐2.7\] (0.7)                                             
  Diarrhea                                                  4 (16.67)                            11 (12.22)                           1.9 \[0.3‐9.5\] (0.5)                                             
  Vomiting                                                  2 (8.33)                             8 (8.89)                             0.9 \[0.1‐10.2\] (0.9)                                            
  Nausea                                                    6 (25)                               27 (30)                              0.8 \[0.2‐2.7\] (0.7)                                             
  Abdominal pain                                            8 (33.33)                            38 (42.22)                           0.6 \[0.1‐3.2\] (0.6)                                             
  Food consumption                                                                                                                                                                                      
  Raw shellfish and mollusks                                4 (16.67)                            3 (3.33)                             19.6 \[2.2‐254\] (0.03)                                           16.7 \[3.6‐90.9\] (0.00)
  Cooked shellfish and mollusks                             1 (4.17)                             2 (2.22)                             1.7 \[0.1‐42.7\] (0.7)                                            
  Tap water                                                 13 (54.17)                           55 (61.11)                           0.6 \[0.1‐1.9\] (0.5)                                             
  Drug consumption before consultation                                                                                                                                                                  
  Antibiotics                                               1 (4.17)                             3 (3.33)                             2.3 \[0.1‐28\] (0.5)                                              
  Antiviral                                                 1 (4.17)                             2 (2.22)                             11.7 \[2.6‐56.8\] (0.007)                                         
  Drug consumption after consultation                                                                                                                                                                   
  Antibiotics                                               7 (29.17)                            8 (8.89)                             5.2 \[1.4‐22\] (0.04)                                             6.4 \[2.1‐19.8\] (0.006)
  Antiviral                                                 4 (16.67)                            6 (6.67)                             2.7 \[0.5‐12.9\] (0.07)                                           7.4 \[1.9‐29\] (0.01)

*P* = .3

Crude odds ratios (ORs) from bivariate models.

aOR = adjusted odds ratios from multivariate models.

CI: confidence interval.

John Wiley & Sons, Ltd

4.1. Microbiological analyses of nasopharyngeal and stool samples of laboratory‐confirmed influenza patients {#irv12523-sec-0020}
------------------------------------------------------------------------------------------------------------

The detailed results from the microbiological investigation are presented in Table [2](#irv12523-tbl-0002){ref-type="table"}. Of the 114 nasopharyngeal samples positive for seasonal influenza viruses, 36.8% (42/114) were influenza A and 63% (72/114) were influenza B. The most frequently identified influenza virus in nasopharyngeal specimens was influenza B Victoria (50%; 57/114) followed by A(H1N1)pdm09 (21%;24/114), influenza B Yamagata (13%;15/114), and A(H3N2) (12.3%;14/114) (Table [2](#irv12523-tbl-0002){ref-type="table"}). Single viral infection accounted for 96.5% (110/114) of nasopharyngeal specimens, whereas multiple infections were observed in 3.5% (4/114). The four coinfections were between A(H1N1)pdm09‐HCoV‐229E, B Victoria‐HCoV‐229E, B Victoria‐HCoV‐OC43, and B Yamagata‐HCoV‐HKU1. Influenza RNA was detected in 21% (24/114) of the 114 stool specimens analyzed. Influenza B Victoria was the most detected virus (7.8%; 9/114) followed by A(H1N1)pdm09 and A(H3N2) (4.3%;5/114, respectively) and influenza B Yamagata (2.6%; 3/114).

###### 

Detection rate of respiratory pathogens in nasopharyngeal and stool samples among the 114 laboratory‐confirmed influenza patients

  Pathogens detected                      Nasopharyngeal sampleN = 114 (%)                   StoolsN = 114 (%)
  --------------------------------------- -------------------------------------------------- --------------------------------------------------
  Influenza A                             42 (36.8)[a](#irv12523-note-0004){ref-type="fn"}   12 (10.5)[b](#irv12523-note-0005){ref-type="fn"}
  *A(H1N1)pdm09*                          24 (21)                                            *5 (4.3)*
  *A(H3N2)*                               14 (12.3)                                          *5 (4.3)*
  Influenza B                             72 (63)                                            12 (10.5)
  *Victoria*                              *57 (50)*                                          *9 (7.8)*
  *Yamagata*                              *15 (13)*                                          *3 (2.6)*
  Human Coronaviruses                     4 (3.5)                                            1 (0.8)
  Human Rhinovirus                        0 (0)                                              1 (0.8)
  Single infections                       110 (96.5)                                         113 (99)
  Coinfections with respiratory viruses   4 (3.5)                                            0 (0)
  *A(H1N1)pdm09 + HCoV‐229E*              *1 (0.8)*                                          
  *Influenza B Victoria+ HCoV‐229E*       *1 (0.8)*                                          
  *Influenza B Victoria+* HCoV‐OC43       *1 (0.8)*                                          
  *Influenza B Yamagata+* HCoV‐HKU1       *1 (0.8)*                                          
  Enteric pathogens                                                                          7 (6.1)
  *HAdV*                                                                                     *2 (1.7)*
  *Astrovirus*                                                                               *2 (1.7)*
  *Sapovirus*                                                                                *3 (2.6)*
  Coinfection with respiratory bacteria   0 (0)                                              0 (0)
  Coinfection with enteric pathogens                                                         1 (0.8)
  *A(H3N2)‐HAdV*                                                                             *1 (0.8)*

4 not subtyped.

2 not subtyped.

John Wiley & Sons, Ltd

Among the other 12 respiratory pathogens tested in stool samples, one specimen was positive for HRV. Enteric pathogens have been detected in 6.1% (7/114) of stools. One coinfection A(H3N2)/HAdV was reported in the stools (Table [2](#irv12523-tbl-0002){ref-type="table"}).

The mean Ct value did not differ between nasopharyngeal samples of patients with influenza RNA‐positive stools (Ct = 25.4 ± 6.4) and patients with influenza RNA‐negative stools (Ct = 25.4 ± 6.7) (*P *=* *1). On average, in a same patient, Ct of influenza virus detection in stool sample had 6.65 more cycles than Ct of influenza virus detection in nasopharynx sample. One discrepancy was found between influenza type detection in stool (influenza A not subtyped) and nasopharyngeal sample (influenza B Yamagata) (Table [3](#irv12523-tbl-0003){ref-type="table"}; ID patient 2). Among the 24 stool samples subjected to viral isolation, none showed virus growth.

###### 

Details of patients with influenza virus\'s codetection in nasopharynx and stool samples

  Patient ID   Laboratory reception date   Week   Age (years)   Sex      Seasonal influenza vaccination   Gastrointestinal symptoms             Chronic disease   Risk factors   Hospitalization   Influenza virus in nasopharyngeal sample   Cycle threshold of influenza virus detected in nasopharyngeal samples   Influenza virus in stools                        Cycle threshold of influenza virus detected in stool samples
  ------------ --------------------------- ------ ------------- -------- -------------------------------- ------------------------------------- ----------------- -------------- ----------------- ------------------------------------------ ----------------------------------------------------------------------- ------------------------------------------------ --------------------------------------------------------------
  1            19/01/2015                  4      1             Male     No                               No                                    No                No             No                Influenza B lineage Yamagata               26                                                                      Influenza B lineage Yamagata                     34
  2            06/02/2015                  6      57            Male     Yes                              No                                    No                Yes            No                Influenza B lineage Yamagata               20                                                                      A NST                                            34
  3            11/02/2015                  7      55            Male     No                               No                                    No                No             No                Influenza B lineage Yamagata               27                                                                      Influenza B lineage Yamagata                     28
  4            12/02/2015                  7      6             Female   No                               No                                    Yes               Yes            Yes               A(H3N2)                                    33                                                                      A(H3N2)                                          34
  5            02/03/2015                  10     52            Female   No                               No                                    No                Yes            No                A(H3N2)                                    25                                                                      A(H3N2)                                          26
  6            22/01/2016                  3      68            Male     No                               No                                    Yes               Yes            Yes               Influenza B lineage Victoria               24                                                                      Influenza B lineage Victoria                     28
  7            26/01/2016                  4      50            Female   No                               No                                    Yes               Yes            No                A(H1N1)pdm2009                             28                                                                      A(H1N1)pdm2009                                   34
  8            03/02/2016                  5      41            Female   No                               No                                    No                No             No                Influenza B lineage Victoria               25                                                                      Influenza B lineage Victoria                     32
  9            24/02/2016                  8      33            Male     No                               No                                    No                No             Yes               Influenza B lineage Victoria               30                                                                      Influenza B lineage Victoria                     32
  10           25/02/2016                  8      52            Male     No                               No                                    No                No             No                Influenza B lineage Victoria               21                                                                      Influenza B lineage Victoria                     32
  11           30/03/2016                  13     55            Male     No                               No                                    No                No             No                Influenza B lineage Victoria               18                                                                      Influenza B lineage Victoria                     27
  12           19/12/2014                  51     2             Male     No                               Diarrhea and abdominal pain           No                No             No                A(H3N2)                                    35                                                                      A(H3N2)                                          35
  13           08/01/2015                  2      80            Female   Yes                              Nausea                                Yes               Yes            No                Influenza B lineage Yamagata               22                                                                      Influenza B lineage Yamagata                     35
  15           21/01/2015                  4      62            Female   No                               Abdominal pain                        No                No             No                A(H3N2)                                    35                                                                      A(H3N2)[a](#irv12523-note-0006){ref-type="fn"}   32
  16           02/02/2015                  6      5             Female   No                               Diarrhea, nausea and abdominal pain   No                No             No                A(H3N2)                                    25                                                                      A(H3N2)                                          33
  17           15/01/2016                  2      10            Female   No                               Nausea and abdominal pain             No                No             No                Influenza B lineage Victoria               22                                                                      Influenza B lineage Victoria                     32
  18           05/02/2016                  5      65            Male     No                               Abdominal pain                        Yes               Yes            No                A(H1N1)pdm2009                             21                                                                      A(H1N1)pdm2009                                   32
  19           10/02/2016                  6      9             Female   No                               Diarrhea                              No                No             No                Influenza B lineage Victoria               23                                                                      Influenza B lineage Victoria                     34
  20           15/02/2016                  7      24            Male     No                               Nausea and abdominal pain             No                No             No                A(H1N1)pdm2009                             34                                                                      A(H1N1)pdm2009                                   32
  21           04/03/2016                  9      43            Male     No                               Vomiting                              No                No             No                A(H1N1)pdm2009                             21                                                                      A(H1N1)pdm2009                                   30
  22           06/03/2016                  9      13            Male     No                               Vomiting and diarrhea                 No                No             No                A NST                                      20                                                                      A NST                                            30
  23           09/03/2016                  10     56            Female   No                               Nausea and abdominal pain             No                No             No                Influenza B lineage Victoria               27                                                                      Influenza B lineage Victoria                     35
  24           12/03/2016                  10     6             Male     No                               Abdominal pain                        No                No             No                Influenza B lineage Victoria               24                                                                      Influenza B lineage Victoria                     30
  25           24/03/2016                  12     54            Male     No                               Nausea                                No                No             No                A(H1N1)pdm2009                             20                                                                      A(H1N1)pdm2009                                   34

Coinfection with HadV.

John Wiley & Sons, Ltd

### 4.1.1. Factors associated with laboratory‐confirmed detection of seasonal influenza viruses in stools {#irv12523-sec-0021}

Bivariate association between the RNA detection of influenza virus in stools (yes/no) in laboratory‐confirmed influenza patients and demographical, clinical, and management factors are presented in Table [1](#irv12523-tbl-0001){ref-type="table"}. Patients who had consumed raw shellfish and/or mollusks or had taken antibiotics after the GP consultation were more likely to have a positive detection of influenza virus RNA in stool (OR = 19.6 \[2.2‐254\], *P *=* *.03; OR = 5.2 \[1.4‐22\], *P *=* *.04) (Table [1](#irv12523-tbl-0001){ref-type="table"}). Among the four patients with exclusively influenza RNA in stools which have consumed raw shellfish and/or mollusks, three declared GI symptoms.

Multivariable analyses reported that hospitalization (aOR = 7.8 \[1.7‐33.7\], *P *=* *.02) was significantly associated with the fecal viral RNA detection (Table [1](#irv12523-tbl-0001){ref-type="table"}). Three patients (12.5% of 24 fecal viral RNA positive) have been hospitalized (ID patient 4, ID patient 6, and ID patient 9, Table [3](#irv12523-tbl-0003){ref-type="table"}). Two of the three hospitalized patients were positive for influenza B Victoria. The third patient was positive for A(H3N2) influenza virus. They were aged between 6 and 68 years, two were male, and two had risks factors of developing influenza complications.

Age between 45 and 64 years (aOR = 4.8 \[1.7‐14.5\], *P *=* *.01), consumption of raw shellfish and/or mollusks (aOR = 16.7 \[3.6‐90.9\], *P *=* *.00), and use of antibiotics (aOR = 6.4 \[2.1‐19.8\], *P *=* *.006) or antiviral treatment (aOR = 7.4 \[1.9‐29\], *P *=* *.01) after the GP consultation were factors significantly associated with an increased odds of the detection of influenza RNA in stools (Table [1](#irv12523-tbl-0001){ref-type="table"}). We noted that the confidence intervals were quite large due to small sample sizes.

5. DISCUSSION {#irv12523-sec-0022}
=============

This study reported for the first time the detection rate of seasonal influenza viruses in stools of laboratory‐confirmed influenza patients of all ages, in general medicine, in France. Clinical characteristics, detection of influenza viruses and other respiratory and enteric pathogens from the upper respiratory tract and in stools concomitantly, management, and risk factors for influenza RNA positivity of stool specimens were investigated.

Results of the present study suggest that age, hospitalization, and food and drug consumption seem to modify odds of detection of influenza RNA in stools of laboratory‐confirmed influenza patients. However, microbiological and clinical characteristics such as influenza virus type, Ct mean values, or GI symptoms seem to not be associated with the influenza RNA positivity of stool specimens. However, we did not report successful recovery of viable influenza virus from stools, boosting the hypothesis that intestinal cells could not support replication of influenza seasonal viruses.[5](#irv12523-bib-0005){ref-type="ref"}, [23](#irv12523-bib-0023){ref-type="ref"}, [24](#irv12523-bib-0024){ref-type="ref"}

Overall, the proportion of influenza viral RNA in stool specimens reported in the present study (21%) was in line with that reported in a recent meta‐analysis (20.6% (95% CI, 8.9‐35.5)).[8](#irv12523-bib-0008){ref-type="ref"} In our study, fecal viral RNA‐positive detection ranged from 8.3% in children aged less than 5 years to 37.5% in adults belonging to the 45‐ to 64‐year age group. We observed that belonging to the age group of 45‐64 years and to be hospitalized increased the odds of detection of influenza virus in stools. This is in line with a previous study reporting positive fecal viral RNA association in stools of hospitalized adults patients,[5](#irv12523-bib-0005){ref-type="ref"} with a detection rate of 32% in patients aged between 50 and 65 years.

The source of influenza viruses in feces and how the viruses pass through the gastrointestinal tract are poorly understood. Swallowing of influenza viruses from the upper respiratory tract and hematogenous dissemination to organs through infected lymphocytes in severe influenza cases are possible explanations for fecal viral RNA detection.[5](#irv12523-bib-0005){ref-type="ref"}, [25](#irv12523-bib-0025){ref-type="ref"}, [26](#irv12523-bib-0026){ref-type="ref"} The increased odds of hospitalization in patients with influenza RNA‐positive stools seems to be more in agreement with the hematogenous dissemination of influenza viruses in severe cases with high viral load.[4](#irv12523-bib-0004){ref-type="ref"}, [27](#irv12523-bib-0027){ref-type="ref"}

A positive association with the consumption of raw shellfish, and/or mollusks, and/or antibiotic and/or antiviral administration was observed. These three factors are known to increase the risk of having diarrhea, vomiting, or mild stomach symptoms resulting from the disruption of the normal microflora from drug consumption[28](#irv12523-bib-0028){ref-type="ref"}, [29](#irv12523-bib-0029){ref-type="ref"} or from the presence of enteric pathogens or toxin in food, or even intolerance to certain seafoods.[30](#irv12523-bib-0030){ref-type="ref"} Similar to other studies, no association was found between GI symptoms and influenza detection.[31](#irv12523-bib-0031){ref-type="ref"}, [32](#irv12523-bib-0032){ref-type="ref"} Interestingly, among the four patients who had influenza RNA exclusively in the stool and had consumed raw shellfish, and/or mollusks, three reported having GI symptoms, but none of the enteric pathogens screened here were detected in their stools. These symptoms could be caused by other enteric pathogens or allergy,[33](#irv12523-bib-0033){ref-type="ref"} intolerance,[34](#irv12523-bib-0034){ref-type="ref"} or toxin[35](#irv12523-bib-0035){ref-type="ref"} responsible for GI symptoms and present on shellfish and mollusks. Among the patients with antibiotic or antiviral drug prescriptions, we did not collect data on GI symptom development after GP consultation, but stool samples were collected 2 days after GP consultation; therefore, patients had started antibiotic and/or antiviral treatment at time of stool collection. We could make the assumption that disruption of the gut microflora leads to an increase in swallowing and gastric flu, which helps influenza viruses reach the lower gastrointestinal tract. A recent study reported that swallowed influenza viruses become resistant to simulated gastric acid and bile/pancreatic juice and could be detected in stools if certain protective mechanisms such as viscous mucus protect it from degradation in the GI tract.[19](#irv12523-bib-0019){ref-type="ref"}

Limitations of this study include the observational study design for which residual bias cannot be excluded, and the small sample size resulting in wide confidence intervals. We did not carry out patient follow‐up to collect clinical information after GP consultation. The detection of influenza virus in stool specimens may have been reduced due to inhibitory material present in the gastrointestinal tract and stool. Ct values are a semiquantitative measure of viral load; thus, it is impossible to assign specific viral loads by pathogens.

Notwithstanding its limits, this is the first prospective multicenter study, with a standardized patient screening and a centralized confirmation of microbiological data and the simultaneous detection of respiratory and enteric pathogens in stool samples, and influenza virus isolation from stools.

We reported for the first time that several factors such as age, hospitalization, and food and drug consumption could play a role in the proportion of influenza‐positive stool samples of influenza laboratory‐confirmed infection patients. The absence of viable influenza viruses in stools seems to agree with reports showing that intestinal cells could not support replication of seasonal influenza viruses. It will be important for studies developing models to identify dissemination route of influenza viruses to GI tract and to evaluate the possibility of intestinal seasonal influenza infection, to take account of these factors.
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